Company
EpiCypher
EpiCypher is dedicated to creating novel platforms that support innovative chromatin research.
Also known as EpiCypher, Inc
- Status
- Operatingas of 2026-09-19Source (opens in a new tab)
- Business model
- B2B
- Founded
- 2012
- Customers
- epigenetics and chromatin biology researchers
- Legal name
- EpiCypher, Inc
- epicypher.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 29 September 2026
About
EpiCypher is an epigenetics company founded in 2012 by Drs. Mark Bedford, Or Gozani, Brian Strahl, and James Bone in response to the growing demand for high-quality reagents and tools to study genomic regulation and enable epigenetics-focused drug discovery.
Funding snapshot
- Total raised
- $3.4MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $3.3M2024-06-27
Funding rounds
- Round, 2024
- $3.3M2024-06-27, SEC form D sold, 1 investor
- Round, 2013
- $30K2013-05-24, SEC form D sold, 2 investors
- Round, 2013
- $35.3K2013-03-06, SEC form D sold, 2 investors
Products
- Other
- CUTANA ChIC / CUT&RUN Assays
- Web
- CUTANA Cloud
- Other
- CUTANA CUT&Tag Assays
- Other
- Fiber-seq Assays
Loading relationship preview